

Paul-Ehrlich-Institute (PEI) grants positive opinion on Provecs Medical's Immunalon®

Immunalon®, a promising new treatment option for solid carcinomas

Hamburg/Langen | 26 April 2010. Provecs Medical recently presented the developmental programme of its novel microenvironment modulating cancer immunotherapeutic Immunalon® to the German Drug Regulatory Department at the Paul-Ehrlich-Institute (Langen). The purpose of the meeting was to seek scientific and regulatory advice regarding the novel therapeutic concept and the planned preclinical and clinical programmes.

„We are pleased about the positive opinion regarding the presented data and developmental plans“, remarked Dr. Frank Schnieders, CEO of Provecs Medical.

Further, the regulatory team supporting Provecs at the Paul Ehrlich Institute meeting stated that they were satisfied that all of the major preclinical and clinical issues relating to the developmental programme for Immunalon® had been addressed.

With this reconfirmed regulatory authority support in place, Provecs Medical believes that it provides potential investors looking to join the current Provecs Series A investment round with a solid basis on which to make their final decisions.

Immunalon® is the first product originating from Provecs Medical's proprietary technology platform. Immunalon® is a novel immunotherapeutic agent that targets the cancer tumor micro-environment, reinstating the immune response within the tumor microenvironment that is needed to destroy the cancer. Immunalon® employs the use of three locally delivered immune system activating agents, thereby providing safe and effective treatment for cancers such as primary and secondary liver cancers that otherwise have few treatment options and a very poor prognosis.

The Paul-Ehrlich-Institute (PEI) is the German Federal Regulatory Agency, responsible for all regulatory issues related to the development of innovative therapies and advanced medicinal products. PEI is able to provide biopharmaceutical companies using advanced technological approaches, such as gene transfer, with sound advice on products planned for the global market.

Provecs Medical is a privately owned biopharmaceutical company founded in 2007 as a spin-out of the University-Medical Center, Hamburg-Eppendorf in Hamburg, Germany. Provecs Medical specializes in the development of novel targeted immunotherapeutics for cancer and infectious diseases.

www.provecs.com

contact: schnieders@provecs.com